Novartis

Vanda begins trial for long-acting injectable to treat schizophrenia

Monday, April 11, 2011 12:52 PM

Vanda Pharmaceuticals and Novartis Pharmaceuticals, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable (or depot) formulation of Fanapt (iloperidone).  This is a phase I study that will evaluate the safety and pharmacokinetic profiles of two different long-acting formulations of Fanapt in patients with schizophrenia.

More... »

Novartis’ Gilenya reduced the risk of MS disability progression, analysis shows

Monday, April 11, 2011 12:44 PM

A new analysis demonstrated that Novartis' Gilenya (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology (AAN).

More... »

Novartis to sell Elidel to Meda

Friday, April 8, 2011 10:56 AM

Switzerland-based Novartis will sell the global rights to manufacture and market Elidel skin cream to Meda Pharmaceuticals, based in Sweden, for an upfront payment of $420 million, according to a Bloomberg report.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

Novartis' hepatitis C treatment shows positive results

Thursday, April 7, 2011 11:38 AM

Novartis' investigational oral agent alisporivir cured almost 50% more previously untreated patients with the most common form of hepatitis C when added to a standard treatment regimen, as reported in phase II data presented at the European Association for the Study of the Liver congress in Berlin.

More... »

Second phase III Novartis JAK inhibitor study meets primary endpoint

Tuesday, March 22, 2011 12:08 PM

Novartis said a pivotal phase III trial of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) has met its primary endpoint of significantly reducing spleen size in patients with myelofibrosis (MF). INC424 is a potent, selective inhibitor of the JAK1 and JAK2 tyrosine kinases.

More... »

Bio-Ball fundraiser joins two communities working

Monday, March 21, 2011 08:00 AM

Can’t dribble, shoot or pass? Don’t worry. Everyone makes the team.

More... »

Novartis to cut 500 jobs in England

Thursday, March 17, 2011 12:33 PM

Novartis has announced plans to shed some 500 positions in the U.K. through an operational restructuring of its site in Horsham, West Sussex, England, according to PharmaTimes.

More... »

Teva: Doctors being contacted for trial of Copaxone copy

Wednesday, March 9, 2011 01:34 PM

Doctors are being contacted to organize a clinical trial for a copy of Teva Pharmaceutical’s multiple sclerosis medicine Copaxone, according to a report in FiercePharma.

More... »

Antisoma’s top management step down

Wednesday, March 2, 2011 08:20 AM

The top management of Antisoma has stepped down, as the British cancer specialist cut its operations following the failure of its two leading drug candidates, Reuters reported.

More... »